Alector drops in after-hours trading after upper-level management shakeup

The company has multiple drugs in a half-dozen clinical trials — and more on the way — to tackle a range of brain diseases, including frontotemporal dementia, Parkinson's and Alzheimer's.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.